Clinical Trial Update: Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Abexinostat in relapsed or refractory Follicular lymphoma is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Abexinostat (Abexinostat)

Snippet

Sponsor: Xynomic Pharmaceuticals, Inc. | Conditions: Follicular Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING